Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact
May 27, 2021

Annual General Meeting 2021

The Annual General Meeting in Oasmia Pharmaceutical AB was held on 27 May 2021. 

Documents

  • Minutes Annual General Meeting 2021 – Oasmia Pharmaceutical AB (in Swedish)
    Swedish May 28, 2021
  • Press release – Report from Annual General Meeting in Oasmia Pharmaceutical AB
    English May 27, 2021
  • Remuneration report 2020
    English May 7, 2021
  • Annual Report 2020
    English April 29, 2021
  • Press release – The Nomination Committee of Oasmia proposes Andrea Buscaglia as new Board member
    English April 27, 2021
  • Information about the proposed Board of Directors for AGM 2021
    English April 27, 2021
  • Postal voting form AGM 2021
    English April 27, 2021
  • Proxy form AGM 2021
    English April 27, 2021
  • The Nomination Committee’s proposals
    English April 27, 2021
  • The Nomination Committee’s reasoned opinion
    English April 27, 2021
  • Notice of Annual General Meeting in Oasmia Pharmaceutical AB
    English April 27, 2021
  • Press release – Nomination Committee appointed for the 2021 Annual General Meeting in Oasmia
    English November 20, 2020

Share this page

Calendar

  • August 12, 2025
    Interim report Q2 2025
  • November 11, 2025
    Interim report Q3 2025
  • February 12, 2026
    Interim report Q4 2025
All events
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com